Loading…
Q-Line Biotech (QLINE)₹516.55−1.95%Medical Equipment & Supplies
At the end of the Jun 2026 quarter, Q-Line Biotech's shareholders were: promoters 67.45%, FIIs 1.68%, DIIs 10.11%, public 20.76%. 0.00% of promoter shares were pledged. It had 3,498 shareholders.
As of · Company filings (shareholding pattern)
| Jun 2026 | |
|---|---|
| Promoters | 67.45% |
| FIIs | 1.68% |
| DIIs | 10.11% |
| Public | 20.76% |
| Promoter shares pledged | 0.00% |
| Number of shareholders | 3,498 |
| Holder | Category | Jun 2026 | Change (pp) |
|---|---|---|---|
| Saurabh Garg | Promoter | 43.66% | — |
| Amita Garg | Promoter | 16.82% | — |
| Ajay Kumar Mahanty | Promoter | 3.24% | — |
| Abhay Agrawal | Promoter | 3.21% | — |
| Vikas Vijaykumar Khemani | Public | 1.86% | — |
| Abakkus Small Cap Fund | DII | 1.44% | — |
| Hem Finlease Private Limited .-Prop | Public | 1.33% | — |
| Market Maker | Public | 1.33% | — |
| Carnelian Aif Category I Trust-Scheme 1 | DII | 1.22% | — |
| Abakkus Flexi Edge Fund-1 | DII | 1.06% | — |
| Calliope Capital Advisors Llp | Public | 0.99% | — |
| Amit Agarwal | Promoter | 0.14% | — |
| Ayush Garg | Promoter | 0.14% | — |
| Shubham Garg | Promoter | 0.14% | — |
| Pushplata Garg | Promoter | 0.09% | — |
Promoters held 67.45% of Q-Line Biotech at the end of the Jun 2026 quarter.
In the Jun 2026 quarter, foreign institutional investors (FIIs) held 1.68% and domestic institutions (DIIs) held 10.11%.
No. The Jun 2026 filing shows no pledged promoter shares.
Q-Line Biotech had 3,498 shareholders at the end of the Jun 2026 quarter.
Vikas Vijaykumar Khemani (Public) held 1.86% at the end of the Jun 2026 quarter, the largest named holding outside the promoter group.